List view / Grid view
Sanofi and Exscientia will develop up to 15 novel drug candidates by leveraging the latter's AI discovery and optimisation platform.
A collaboration aims to utilise a compound library of 15,000 clinically-ready molecules and screen then against three COVID-19 targets.
The first drug designed using artificial intelligence (AI) has moved into its Phase I trial. Professor Andrew Hopkins of Exscientia explains how an algorithm was used to achieve this milestone.
Charlotte Walker-Osborn, a Partner and Head of Technology Sector (International) at global law-firm Eversheds Sutherland and a legal expert in technology law, explains some of the challenges and potential future of artificial intelligence (AI) in the field of drug discovery.
Exscientia has agreed a strategic research collaboration, and licence option agreement with Sanofi in the high-interest area of metabolic disease.